What is the primary mechanism of action of TNF-alpha inhibitors in rheumatologic diseases?
Master all 25 flashcards
Mechanisms, indications, and adverse effects of biologic and targeted immunotherapies.
Mastering this deck enables clinicians to understand the mechanistic basis of biologic therapies, select appropriate treatments for specific rheumatologic conditions, and anticipate potential adverse effects, thereby improving patient management and outcomes in complex cases.
ℹ️ Educational Use Only: This flashcard deck is created by usersof our platform for their educational and study purposes. The content is not intended as medical advice, diagnosis, or treatment guidance. Always consult qualified healthcare professionals for medical decisions and verify information with authoritative medical sources.
Showing 20 of 25 cardsSample view
| # | Front | Back | Hint |
|---|---|---|---|
| 1 | What is the primary mechanism of action of TNF-alpha inhibitors in rheumatologic diseases? | TNF-alpha inhibitors block the activity of tumor necrosis factor-alpha, a pro-inflammatory cytokine involved in the pathogenesis of diseases like rheumatoid arthritis and psoriatic arthritis, thereby reducing inflammation and joint destruction. | Think of TNF-alpha inhibitors as 'cytokine blockers' that dampen inflammation. |
| 2 | Name two common biologic agents that target B cells in rheumatology and their indications. | Rituximab and Belimumab are biologics targeting B cells; rituximab depletes CD20+ B cells and is used in rheumatoid arthritis and vasculitis, while Belimumab inhibits B-cell activating factor (BAFF) and is approved for systemic lupus erythematosus. | Remember 'Rituximab' as 'R for deplete' and 'Belimumab' as 'B for B-cell activation'. |
| 3 | What are the main adverse effects associated with biologic therapies in rheumatology? | Adverse effects include increased risk of infections (e.g., TB, opportunistic infections), infusion reactions, hypersensitivity, development of autoantibodies, and rarely, progressive multifocal leukoencephalopathy (PML). | Monitor for infections; immunosuppression is a key concern. |
| 4 | Which targeted therapy inhibits Janus kinase (JAK) enzymes, and what is its role in rheumatologic treatment? | JAK inhibitors, such as Tofacitinib and Upadacitinib, block JAK enzymes involved in cytokine signaling pathways, reducing inflammation in rheumatoid arthritis, especially in patients who fail traditional DMARDs. | JAK inhibitors are 'small molecules' that interfere with intracellular signaling. |
| 5 | What is the mechanism of action of IL-6 receptor antagonists like Tocilizumab? | IL-6 receptor antagonists block the interleukin-6 receptor, preventing IL-6 from exerting its pro-inflammatory effects, thus reducing systemic inflammation in diseases like rheumatoid arthritis and giant cell arteritis. | Think of IL-6 as a 'fire starter' in inflammation; blocking its receptor dampens the fire. |
| 6 | In which rheumatologic condition is Abatacept, a CTLA-4 Ig fusion protein, primarily used, and how does it work? | Abatacept is primarily used in rheumatoid arthritis; it inhibits T-cell activation by blocking the CD80/CD86 co-stimulatory signal necessary for T-cell activation via CTLA-4 engagement. | Abatacept 'turns down' T-cell activation, like a 'brake' on immune response. |
| 7 | What are the main risks associated with biologic therapies targeting immune checkpoints? | These therapies can impair immune surveillance, increasing the risk of infections and possibly leading to malignancies due to decreased immune regulation. | Checkpoint inhibitors 'release brakes' on immune cells; balance is key. |
| 8 | How do targeted therapies differ from traditional DMARDs in rheumatology? | Targeted therapies specifically inhibit cytokines or immune cell pathways involved in disease pathogenesis, often with faster onset and more precise mechanisms compared to broad-spectrum traditional DMARDs like methotrexate. | Think of targeted therapies as 'precision tools' versus 'broad-spectrum' traditional drugs. |
| 9 | Which biologic agent is associated with the highest risk of reactivating latent tuberculosis? | TNF-alpha inhibitors, such as infliximab and adalimumab, are associated with a significant risk of reactivating latent TB due to their role in granuloma maintenance. | Pre-treatment TB screening is essential before starting TNF inhibitors. |
| 10 | What is the role of IL-1 inhibitors like Anakinra in rheumatology, and in which conditions are they used? | IL-1 inhibitors block interleukin-1 activity, reducing inflammation; they are used in autoinflammatory syndromes like adult-onset Still's disease and recurrent pericarditis. | IL-1 is a 'pyrogenic' cytokine; blocking it reduces fever and inflammation. |
| 11 | Describe the concept of 'biosimilars' in biologic therapy. | Biosimilars are highly similar to an FDA-approved biologic (reference product) with no clinically meaningful differences in safety, purity, or potency; they offer cost-effective alternatives to original biologics. | Think of biosimilars as 'generic' versions of biologics, though not identical like small-molecule generics. |
| 12 | Why is monitoring for hepatitis B reactivation important in patients receiving biologic therapies? | Biologics, especially anti-TNF agents, can suppress immune responses, leading to reactivation of latent hepatitis B virus, which can cause severe hepatitis or fulminant liver failure. | Pre-treatment screening for hepatitis B is recommended; consider antiviral prophylaxis if needed. |
| 13 | What is the rationale for combining biologic therapies with conventional DMARDs? | Combining biologics with DMARDs, such as methotrexate, can enhance efficacy, reduce immunogenicity (antibody formation against biologics), and improve clinical outcomes. | Combination therapy often achieves better disease control than monotherapy. |
| 14 | Which biologic agent is used in the treatment of systemic sclerosis-associated interstitial lung disease (ILD)? | Nintedanib, a tyrosine kinase inhibitor, has been approved to slow the progression of ILD in systemic sclerosis, although it is not a biologic; biologics like tocilizumab may also have roles. | Focus on antifibrotic agents; biologic use is investigational in this context. |
| 15 | How do Janus kinase (JAK) inhibitors influence cytokine signaling pathways? | JAK inhibitors block the Janus kinase enzymes involved in the JAK-STAT signaling pathway, which transmits signals from various cytokine receptors to promote inflammation, thereby reducing cytokine-driven inflammation. | Think of JAK inhibitors as 'interrupting' cytokine messages inside the cell. |
| 16 | What is the significance of anti-drug antibodies in biologic therapy? | Anti-drug antibodies can develop against biologic agents, reducing their efficacy and increasing the risk of infusion reactions; concomitant immunosuppressants can mitigate this risk. | Monitor for antibodies if biologic response diminishes. |
| 17 | Name an adverse effect specific to IL-6 inhibitors like Tocilizumab. | IL-6 inhibitors can cause elevated liver enzymes, cytopenias, and increased risk of infections, including serious bacterial and fungal infections. | Regular monitoring of blood counts and liver function tests is essential. |
| 18 | Which biologic therapy is contraindicated in patients with a history of demyelinating disease? | TNF-alpha inhibitors are generally contraindicated or used with caution in patients with a history of demyelinating diseases like multiple sclerosis due to potential exacerbation. | Consider alternative therapies if demyelinating disease is present. |
| 19 | Describe the role of targeted therapies in the management of vasculitis syndromes. | Targeted therapies, such as rituximab, are used to deplete B cells in ANCA-associated vasculitis, reducing autoantibody production and controlling disease activity, especially in refractory cases. | B-cell depletion is a key strategy in certain vasculitides. |
| 20 | What are the considerations for vaccination in patients receiving biologic therapies? | Live vaccines are generally contraindicated due to immunosuppression; inactivated vaccines can be administered, ideally before starting biologics, to prevent infections. | Plan vaccinations before initiating immunotherapy whenever possible. |
Note: This preview shows only the first 20 cards. The complete deck contains 25 total cards. Start studying to access all flashcards.
Master all 25 flashcards
Explore other decks you might find helpful